Akebia Therapeutics Inc’s filing revealed that its Officer Ostrowski Erik acquired Company’s shares for reported $0.15 million on Jun 30 ’25. In the deal valued at $3.67 per share,41,314 shares were bought.
Then, Malabre Richard C sold 15,000 shares, generating $60,150 in total proceeds. Upon selling the shares at $4.01, the SVP, Chief Accounting Officer now owns 266,914 shares.
Before that, Malabre Richard C sold 13,334 shares. Akebia Therapeutics Inc shares valued at $47,069 were divested by the SVP, Chief Accounting Officer at a price of $3.53 per share. As a result of the transaction, Malabre Richard C now holds 266,914 shares, worth roughly $0.97 million.
A number of analysts have revised their coverage, including Leerink Partners’s analysts, who began to cover the stock in late April with a ‘”an Outperform”‘ rating. Jefferies began covering AKBA with “Buy” recommendation on April 01, 2025.
Price Performance Review of AKBA
On Monday, Akebia Therapeutics Inc [NASDAQ:AKBA] saw its stock fall -0.27% to $3.64. Akebia Therapeutics Inc shares have risen nearly 293.64% since the year began. Nevertheless, the stocks have risen 91.58% over the past one year. While a 52-week high of $4.08 was reached on 06/09/25, a 52-week low of $0.91 was recorded on 04/10/25.
Levels Of Support And Resistance For AKBA Stock
The 24-hour chart illustrates a support level at 3.60, which if violated will result in even more drops to 3.56. On the upside, there is a resistance level at 3.71. A further resistance level may holdings at 3.78.
How much short interest is there in Akebia Therapeutics Inc?
A steep rise in short interest was recorded in Akebia Therapeutics Inc stocks on 2025-06-13, dropping by -1.22 million shares to a total of 18.5 million shares. Yahoo Finance data shows the prior-month short interest on 2025-05-15 was 19.72 million shares. There was a decline of -6.62%, which implies that there is a negative sentiment for the stock.
